Detection of actionable mutations in circulating tumor DNA for non-small cell lung cancer patients by Paul van der Leest, Pim Rozendal, Naomi Rifaela, Anthonie J. van der Wekken, Hanneke Kievit, Vincent D. de Jager, Grigory Sidorenkov, Léon C. van Kempen, T. Jeroen N. Hiltermann, Ed Schuuring

Get full text

Quality of life, neurocognitive functioning, psychological issues, sexuality and comorbidity more than 2 years after commencing immune checkpoint inhibitor treatment by Melanie M van der Klauw, T Jeroen N Hiltermann, Mathilde Jalving, Emoke Racz, Sjoukje Oosting, Anna K L Reyners, Wellington Candido, Annemarie Cecile Eggen, Ingeborg Bosma, Reinate D Horinga, Kelly C van Heuvelen, Janine Nuver

Get full text

Prognostic Value of KRAS/TP53 Status for Overall Survival in First-Line Monoimmunotherapy and Chemoimmunotherapy Treated Patients With Nonsquamous NSCLC in the Netherlands: A Brief... by Vincent D. de Jager, MD, Léon C. van Kempen, PhD, Betzabel N. Cajiao Garcia, MSc, T. Jeroen N. Hiltermann, MD, PhD, Anthonie J. van der Wekken, MD, PhD, Ed Schuuring, PhD, Stefan M. Willems, MD, PhD

Get full text

Pemphigoid diseases as immune-related adverse effect following immune checkpoint inhibitors: A clinical case series of a diverse spectrum by Nika Kotnik, MD, Gilles F.H. Diercks, MD, PhD, Hilde Jalving, MD, PhD, Geke A.P. Hospers, MD, PhD, Sjoukje F. Oosting, MD, PhD, Michel van Kruchten, MD, PhD, T. Jeroen N. Hiltermann, MD, PhD, Maria C. Bolling, MD, PhD, Jeroen Bremer, PhD, Barbara Horváth, MD, PhD, Joost M. Meijer, MD, PhD

Get full text